| Biological Industries (IL)–Sartorius: investment, 201912 acquisition of just over 50% for €45m in cash with option to acquire further 20% |
2019-12-05 |
| Indivumed–Biognosys: MS-based proteomics, 201912– collab integration of HRM MS proteomics data into multi-omics IndivuType cancer database |
2019-12-02 |
| ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB |
2019-11-29 |
| ViGeneron–MC Services: public relations, 201911 service existent media + investo relations by MC Services |
2019-11-28 |
| ViGeneron–Sequoia Capital: investment, 201911 financing round Series A incl co-lead investor Sequoia Capital China |
2019-11-28 |
| ViGeneron–SEVERAL: investment, 201911 financing round Series A co-led by WuXi AppTec + Sequoia Capital China |
2019-11-28 |
| ViGeneron–WuXi PharmaTech: investment, 201911 financing round Series A incl co-lead investor WuXi AppTec |
2019-11-28 |
| MaxiVax–EU (govt): grant, 201911 Horizon 2020 EIC Accelerator grant €2.785m |
2019-11-26 |
| MaxiVax–SEVERAL: investment, 201911 financing round Series B2 CHF5m from existing + new investors |
2019-11-26 |
| Ferring–Blackstone: investment, 201911– investment $400m by Blackstone Life Sciences in FerGene to develop + market nadofaragene firadenovec |
2019-11-25 |
| Medicines Company–Novartis: investment, 201911– cash tender offer $9.7b at $85/share ANNOUNCED |
2019-11-24 |
| Immunitas Therapeutics–Bayer: investment, 201911 financing round Series A totalling $39m incl co-lead investor Leaps by Bayer |
2019-11-21 |
| Immunitas Therapeutics–Evotec: investment, 201911 financing round Series A totalling $39m incl co-investor Evotec |
2019-11-21 |
| Immunitas Therapeutics–Merck (DE): investment, 201911 financing round Series A totalling $39m incl co-investor M Ventures |
2019-11-21 |
| Immunitas Therapeutics–Novartis: investment, 201911 financing round Series A totalling $39m incl co-lead investor Novartis Venture Fund |
2019-11-21 |
| Immunitas Therapeutics–SEVERAL: investment, 201911 financing round Series A $39m co-led by Leaps by Bayer + Novartis Venture Fund |
2019-11-21 |
| LabCorp–Qiagen: bioinformatics, 201911– license extension with HGMD in addition ot Qiagen Clinical Insights |
2019-11-20 |
| CRISPR Therapeutics–SEVERAL: investment, 201911 public offering up to $315.25m with 4.25m+637.5k common shares at $64.5/share |
2019-11-19 |
| Rodin Therapeutics–Alkermes: investment, 201911 acquisition $100m upfront cash + $850m milestones by Alkermes |
2019-11-18 |
| Turbine–Atlantic Labs: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Atlantic Labs Manager GmbH |
2019-11-13 |
| Turbine–Delin Ventures: investment, 201911 first institutional financing round totalling €3m incl lead investor Delin Ventures |
2019-11-13 |
| Turbine–o2h: investment, 201911 first institutional financing round totalling €3m incl new + co-investor o2h Ventures |
2019-11-13 |
| Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Esther Dyson |
2019-11-13 |
| Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Vishal Gulati |
2019-11-13 |
| Turbine–SEVERAL: investment, 201911 first institutional financing round €3m led by Delin Ventures + incl Atlantic Labs et al. |
2019-11-13 |
| Evotec–Merck (DE): CRISPR technology, 201911– license to CRISPR IP portfolio from Merck to Evotec |
2019-11-12 |
| Immatics–Genedata: bioinformatics, 201911– license to Genedata Biologics for use with Xceptor TCR discovery + engineering platform |
2019-11-12 |
| NEC–Vaximm: cancer vaccines, 201911– collab + option agreem for personalised neoantigen cancer vaccines |
2019-11-12 |
| Vaximm–NEC: investment, 201911 equity investment by NEC in connection with collab + option agreem |
2019-11-12 |
| Expedeon–Abcam: investment, 201911– acquisition €120m cash of immunology + proteomics business of Expedeon by Abcam ANNOUNCED |
2019-11-11 |
| eGenesis–Bayer: investment, 201911 financing round Series B totalling $100m incl new + co-investor Leaps by Bayer |
2019-11-07 |
| eGenesis–Fresenius: investment, 201911 financing round Series B totalling $100m incl lead investor Fresenius Medical Care Ventures |
2019-11-07 |
| eGenesis–SEVERAL: investment, 201911 financing round Series B $100m led by Fresenius Medical Care Ventures |
2019-11-07 |
| eGenesis–Wellington Partners: investment, 201911 financing round Series B totalling $100m incl new + co-investor Wellington Partners |
2019-11-07 |
| Owlstone–Thermo Fisher: mass spectrometry, 201911– collab integration of Q Exactive GC Hybrid Quad-Orbitrap MS into Breath Biopsy platform |
2019-11-07 |
| Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA |
2019-11-06 |
| Vifor Pharma–Evotec: drug r+d, 201911– collab establishment 50/50 joint venture for nephrology treatments using NURTuRE biobank + PanHunter s/w |
2019-11-06 |
| Pieris–BVF Partners: investment, 201911 private placement totalling $32m incl existing + lead investor BVF Partners |
2019-11-04 |
| Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners |
2019-11-04 |
| Saniva Diagnostics–Xlife Sciences: investment, 201911 investment by Xlife Sciences AG in Saniva Diagnostics GmbH |
2019-11-04 |
| Roivant–Sumitomo: investment, 201910 acquisition 10% stake in Roivant by Sumitomo Dainippon Pharma in connection w strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Altavant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Enzyvant Therapeutics by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Myovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Spirovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Urovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance |
2019-10-31 |
| Sumitomo–Roivant: drug development, 201910– collab strategic alliance $3b upfront incl transfer of 5 vants to Sumitomo Dainippon Pharma |
2019-10-31 |
| AstraZeneca–BBG/Braun Group: quetiapine fumarate, 201910– acquisition $178m upfront + up to $61m rights to Seroquel/XR in Europe + RU by Cheplapharm |
2019-10-30 |
| Centogene–SEVERAL: investment, 201910–201911 IPO $56m+$8.4m with 4m+600k comon shares at $14/share at Nasdaq Global Market |
2019-10-28 |
| OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m |
2019-10-23 |
| MCG Motion Capture–Akampion: public relations, 201910 service existent by Akampion |
2019-10-22 |
| MCG Motion Capture–Biotech Alliances International: investment banking, 201910– service excl for planned $15m Series A Round of MCG |
2019-10-22 |
| MCG Motion Capture–SEVERAL: investment, 201910– PLANNED financing round Series A $15m |
2019-10-22 |
| Arcutis Biotherapeutics–HBM: investment, 201910 financing round Series C totalling $94.5m incl new + lead investor HBM Healthcare Investments |
2019-10-21 |
| Arcutis Biotherapeutics–SEVERAL: investment, 201910 financing round Series C $94.5m led by HBM Healthcare Investments |
2019-10-21 |
| Danaher–Sartorius: investment, 201910– acquisition $750m three life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal |
2019-10-21 |
| Plexium–Merck (DE): investment, 201910 financing round Series A totalling $28m incl co-investor M Ventures |
2019-10-17 |
| Plexium–SEVERAL: investment, 201910 financing round Series A $28m co-led by DCVC Bio + The Column Group |
2019-10-17 |
| Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund |
2019-10-17 |
| Healx–Amadeus Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Amadeus Capital Partners |
2019-10-16 |
| Healx–Balderton Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Balderton Capital |
2019-10-16 |
| Healx–btov Partners: investment, 201910 financing round Series B totalling $56m incl new + co-investor btov Partners |
2019-10-16 |
| Healx–PERSON: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Jonathan Milner |
2019-10-16 |
| Healx–SEVERAL: investment, 201910 financing round Series B $56m led by new investor Atomico |
2019-10-16 |
| Abalos Therapeutics–Boehringer: investment, 201910 financing round Series A totalling €12m invl co-lead investor BIVF |
2019-10-15 |
| Abalos Therapeutics–High-Tech Gründerfonds: investment, 201910 financing round Series A totalling €12m incl co-investor HTGF |
2019-10-15 |
| Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-investor NRW.BANK |
2019-10-15 |
| Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-lead investor Gründerfonds Ruhr |
2019-10-15 |
| Abalos Therapeutics–SEVERAL: investment, 201910 financing round Series A €12m co-led by BIVF + Gründerfonds Ruhr |
2019-10-15 |
| Abalos Therapeutics–Trophic Communications: public relations, 201910 service existent by Trophic |
2019-10-15 |
| CRISPR Therapeutics–KSQ Therapeutics: CRISPR-based cell therapy, 201910– cross-licensing €na genome editing + CAR-T cell therapy IP |
2019-10-15 |
| Biocon–Evotec: biosimilars, 201910– license €na to Biocon Biologics for pre-clinical biosimilar asset of Just-Evotec Biologics |
2019-10-10 |
| FloDesign Sonics–Merck (DE): investment, 201910 acquisition €na by Merck |
2019-10-10 |
| Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health |
2019-10-09 |
| Parexel–Roivant: healthcare informatics, 201910– collab with Datavant multi-year strategic alliance integration of real-world with clinical trial data |
2019-10-09 |
| Bayer–RIKEN: drug discovery, 201910– strategic collaboration incl drug target discovery of Bayer Open Innovation Center Japan + RIKEN Innovation |
2019-10-08 |
| GSK–Lyell Immunopharma: cancer cell therapy, 201910–202409 collab 5y developm of technologies to improve cancer cell therapies |
2019-10-08 |
| Vivoryon–MC Services: public relations, 201910 service existent by MC Services |
2019-10-08 |
| Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG |
2019-10-08 |
| Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys |
2019-10-08 |
| 4SC–SEVERAL: investment, 201910 capital increase €22.4m net €22m with 10.65m new shares at €2.1/share with subscription rights |
2019-10-07 |
| 4SC–Strüngmann Group: investment, 201910 capital increase totalling €22.4m net €22m incl subscription rights for Santo Holding + ATS |
2019-10-07 |
| Dalhousie Univ–Thermo Fisher: mass spectrometer, 201910 supply C$1.3m of Orbitrap Fusion MS system to MS + Proteomics Core Faclity |
2019-10-07 |
| Illumina–Qiagen: sequencing-based IVD tests, 201910–2034 collab 15y strategic alliance combining sequencing technology + assays + automation + s/w |
2019-10-07 |
| Lundbeck–LeadXPro: drug discovery services, 201910– collab structural proteomics services using X-ray + cryo-EM for small molecule drug discovery |
2019-10-07 |
| Rentschler–Sumitomo: biologics contract manufacturing, 201910– collab expansion SPI supports marketing + delivery of Rentschler CDMO services in Japan |
2019-10-04 |
| Aeovian Pharmaceuticals–Apollo Ventures: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Apollo Health Ventures |
2019-10-03 |
| Aeovian Pharmaceuticals–Evotec: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Evotec |
2019-10-03 |
| Aeovian Pharmaceuticals–SEVERAL: investment, 201910 financing round Series A $37m led by VenBio + Sofinnova Investments |
2019-10-03 |
| Aeovian Pharmaceuticals–Sofinnova: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor Sofinnova Investments |
2019-10-03 |
| Aeovian Pharmaceuticals–VenBio: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor VenBio Partners |
2019-10-03 |
| Freiberg Instruments–Bruker Corp: investment, 201910 acquisition €na of Magnettech EPR business by Bruker |
2019-10-02 |
| Cellectis–Lonza: cell therapy contract manufacturing, 201910– supply UCART cell therapy candidates by Lonza in Geleen (NL) |
2019-10-01 |
| Eisai–Numab: antibody cancer drug, 201910– collab + license option ww excl developing multi-specific Abs using MATCH platform |
2019-10-01 |
| Novartis–Microsoft: artificial intelligence, 201910– collab strategic multiyear AI for drug r+d + commercialisation |
2019-10-01 |
| Creoptix–SEVERAL: investment, 201909 financing round Series 1st closing CHF8m incl investors Swisscanto Invest + Waters |
2019-09-30 |
| Creoptix–Waters: investment, 201909 financing round Series 1st closing totalling CHF8m incl existing + co-investor Waters Corp |
2019-09-30 |
| Creoptix–Zürcher Kantonalbank: investment, 201909 financing round Series 1st closing totalling CHF8m incl new + lead investor Swisscanto Invest |
2019-09-30 |
| STipe Therapeutics–SEVERAL: investment, 201909 financing round Series A €20m co-led by Arix Bioscience + Novo Holdings |
2019-09-30 |
| Roper Technologies–AMETEK: investment, 201909– acquisition $925m in cash of Gatan Inc from Roper Technologies by AMETEK |
2019-09-27 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
